PCSK9 and breast carcinoma: A Mendelian randomized grouping experiment proved that genetically elevated LDL-C due to proprotein convertase subtilisin/kexin type 9 (PCSK9) gene mutations could increase the incidence of estrogen receptor-positive breast cancer.